Avammune Therapeutics Raises Series A Funding

healthcareAvammune Therapeutics Inc., (formerly known as Straximm Therapeutics), a Philadelphia, PA-based drug discovery company, raised its undisclosed Series A funding.

The round was raised through a consortium of private investors.

Led by Arun B Papaiah, MBA, Founder and Chief Executive Officer, Aditya Kulkarni, Ph.D., Founder and Chief Scientific Officer, and Srinivasan Namala, Founder and Director, Avammune Therapeutics is a drug discovery company focused on the development of systemically administered small molecule modulators of the STING pathway to harness the immune system for fighting cancer.

Avammune, a spin-off from Aten Porus Lifesciences (Bangalore, India), also announced the appointment of its scientific advisory board comprised of:
– Prof. George Church, a Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET).
– Prof. Kate Fitzgerald, a Professor of Medicine, Director of the Program in Innate Immunity and The Worcester Foundation Chair in Biomedical Sciences at the University of Massachusetts (Amherst) Medical School.
– Prof. Jean-François Paquin, who studied chemistry at the Université Laval where he graduated with a BSc degree.



Join the discussion